# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-25-060074
Filing Date
2025-04-29
Accepted
2025-04-29 16:00:16
Documents
16
Period of Report
2025-04-29

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | crdf-20250429.htm iXBRL | DEF 14A | 1421468
2 | GRAPHIC | img98646248_0.jpg | GRAPHIC | 140832
3 | GRAPHIC | img98646248_1.jpg | GRAPHIC | 303138
4 | GRAPHIC | img98646248_2.jpg | GRAPHIC | 305727
| Complete submission text file | 0000950170-25-060074.txt |  | 4320378

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
5 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | crdf-20250429.xsd | EX-101.SCH | 8189
18 | EXTRACTED XBRL INSTANCE DOCUMENT | crdf-20250429_htm.xml | XML | 382891

Mailing Address 11055 FLINTKOTE AVENUE SAN DIEGO CA 92121
Business Address 11055 FLINTKOTE AVENUE SAN DIEGO CA 92121 858-952-7570
Cardiff Oncology, Inc. (Filer) CIK: 0001213037 (see all company filings)

EIN.: 272004382 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-35558 | Film No.: 25886935
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)